What is Immunotech Laboratories, Inc. (IMMB) stock price today?

Immunotech Laboratories, Inc. (IMMB) is currently trading at $0.00.

What is IMMB P/E ratio?

Immunotech Laboratories, Inc.'s P/E ratio is -0.22. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is IMMB return on equity (ROE)?

Immunotech Laboratories, Inc.'s return on equity (ROE) is 0.00%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.

What is Immunotech Laboratories, Inc.'s market cap?

Immunotech Laboratories, Inc. has a market capitalization of $114993.

OTC · Biotechnology

Immunotech Laboratories, Inc. (IMMB) Stock

$0.00 OTC: IMMB Healthcare

Valuation

Metric	Value
Price	$0.00
Market Cap	$114993
P/E Ratio	-0.22
P/B Ratio	0.02
P/S Ratio	0.00
EPS (TTM)	$-0.59
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	0.00%
ROA	-4.68%
ROCE	-7.30%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.40
Current Ratio	0.01

Annual Financials (USD)

Metric	2004	2005	2009	2013	2016
Revenue	$0	$0	$0	$0	$0
Operating Profit	$0	$-2.0M	$-1.0M	$-1.0M	$0
Net Profit	$0	$-34.0M	$-1.0M	$-1.0M	$0
EPS	$-43.00	$-802.00	$0.00	$0.00	$0.00
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2004	2005	2009	2013	2016
Total Assets	$0	$0	$10.0M	$11.0M	$11.0M
Total Liabilities	$1.0M	$1.0M	$4.0M	$5.0M	$6.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$1.0M	$2.0M	$2.0M

Cash Flow (USD)

Metric	2004	2005	2009	2013	2016
Operating Cash Flow	$0	$0	—	$0	$0
Investing Cash Flow	$0	$0	—	$0	$0
Financing Cash Flow	$0	$0	—	$0	$0
Net Cash Flow	$0	$0	—	$0	$0
Free Cash Flow	$0	$0	$0	$0	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-5.55
FCF Yield	-27.10%
Quick Ratio	0.00
Interest Coverage	-20.75
Return 1Y	100.00%
Return 3Y	-66.67%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BIOIFBiome Grow Inc.	$0.00	—	-0.01	$56208	0.00%
CBGLCannabis Global Inc.	$0.00	—	-3.40	$56821	0.00%
HADVHealth Advance Inc.	$0.00	—	2.00	$32189	0.00%
IPAHInterpharm Holdings, Inc.	$0.00	—	—	$660	0.00%
MHTXManhattan Scientifics, Inc.	$0.00	—	-0.05	$55928	0.00%

About Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.

Immunotech Laboratories, Inc. (IMMB) stock trades at $0.00 with a market capitalization of $114993. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.22, reflecting a net loss over the last twelve months, price-to-book of 0.02, price-to-sales of 0.00.

On profitability, Immunotech Laboratories, Inc. generates a return on equity (ROE) of 0.00%, return on capital employed of -7.30%.

Official website: www.immunotechlab.com